BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 21041733)

  • 1. Blockade of programmed death-1 in young (New Zealand black x New Zealand white)F1 mice promotes the activity of suppressive CD8+ T cells that protect from lupus-like disease.
    Wong M; La Cava A; Singh RP; Hahn BH
    J Immunol; 2010 Dec; 185(11):6563-71. PubMed ID: 21041733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. pConsensus peptide induces tolerogenic CD8+ T cells in lupus-prone (NZB x NZW)F1 mice by differentially regulating Foxp3 and PD1 molecules.
    Singh RP; La Cava A; Hahn BH
    J Immunol; 2008 Feb; 180(4):2069-80. PubMed ID: 18250412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses.
    Kitazawa Y; Fujino M; Wang Q; Kimura H; Azuma M; Kubo M; Abe R; Li XK
    Transplantation; 2007 Mar; 83(6):774-82. PubMed ID: 17414712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation.
    Currie AJ; Prosser A; McDonnell A; Cleaver AL; Robinson BW; Freeman GJ; van der Most RG
    J Immunol; 2009 Dec; 183(12):7898-908. PubMed ID: 20007574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.
    Mangsbo SM; Sandin LC; Anger K; Korman AJ; Loskog A; Tötterman TH
    J Immunother; 2010 Apr; 33(3):225-35. PubMed ID: 20445343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of programmed death-1 in young (New Zealand Black x New Zealand White)F1 mice promotes the suppressive capacity of CD4+ regulatory T cells protecting from lupus-like disease.
    Wong M; La Cava A; Hahn BH
    J Immunol; 2013 Jun; 190(11):5402-10. PubMed ID: 23636058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response.
    Early GS; Zhao W; Burns CM
    J Immunol; 1996 Oct; 157(7):3159-64. PubMed ID: 8816428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection against renal disease in (NZB x NZW)F(1) lupus-prone mice after somatic B cell gene vaccination with anti-DNA immunoglobulin consensus peptide.
    Ferrera F; Hahn BH; Rizzi M; Anderson M; Fitzgerald J; Millo E; Indiveri F; Shi FD; Filaci G; La Cava A
    Arthritis Rheum; 2007 Jun; 56(6):1945-53. PubMed ID: 17530718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed cell death 1 (PD-1) and its ligand PD-L1 are required for allograft tolerance.
    Wang L; Han R; Hancock WW
    Eur J Immunol; 2007 Oct; 37(10):2983-90. PubMed ID: 17899549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4+ T cell lines with selective patterns of autoreactivity as well as CD4- CD8- T helper cell lines augment the production of idiotypes shared by pathogenic anti-DNA autoantibodies in the NZB x SWR model of lupus nephritis.
    Sainis K; Datta SK
    J Immunol; 1988 Apr; 140(7):2215-24. PubMed ID: 2965184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Keratinocyte-associated B7-H1 directly regulates cutaneous effector CD8+ T cell responses.
    Ritprajak P; Hashiguchi M; Tsushima F; Chalermsarp N; Azuma M
    J Immunol; 2010 May; 184(9):4918-25. PubMed ID: 20363965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resting B cells from autoimmune lupus-prone New Zealand Black and (New Zealand Black x New Zealand White)F1 mice are hyper-responsive to T cell-derived stimuli.
    Jongstra-Bilen J; Vukusic B; Boras K; Wither JE
    J Immunol; 1997 Dec; 159(12):5810-20. PubMed ID: 9550377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus.
    Hahn BH; Singh RR; Wong WK; Tsao BP; Bulpitt K; Ebling FM
    Arthritis Rheum; 2001 Feb; 44(2):432-41. PubMed ID: 11229475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD8+ T cell-mediated suppression of autoimmunity in a murine lupus model of peptide-induced immune tolerance depends on Foxp3 expression.
    Singh RP; La Cava A; Wong M; Ebling F; Hahn BH
    J Immunol; 2007 Jun; 178(12):7649-57. PubMed ID: 17548601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-mediated signaling through PD-1 costimulates T cells and enhances CD28-dependent proliferation.
    del Rio ML; Penuelas-Rivas G; Dominguez-Perles R; Ramirez P; Parrilla P; Rodriguez-Barbosa JI
    Eur J Immunol; 2005 Dec; 35(12):3545-60. PubMed ID: 16285013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bcl-xL is required for the development of functional regulatory CD4 cells in lupus-afflicted mice following treatment with a tolerogenic peptide.
    Sharabi A; Lapter S; Mozes E
    J Autoimmun; 2010 Mar; 34(2):87-95. PubMed ID: 19596183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and Molecular Phenotypes of pConsensus Peptide (pCons) Induced CD8
    Singh RP; Hahn BH; Bischoff DS
    Front Immunol; 2021; 12():718359. PubMed ID: 34867947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulating PD-1-negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival.
    Gao W; Demirci G; Strom TB; Li XC
    Transplantation; 2003 Sep; 76(6):994-9. PubMed ID: 14508368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutting edge: programmed death-1 defines CD8+CD122+ T cells as regulatory versus memory T cells.
    Dai H; Wan N; Zhang S; Moore Y; Wan F; Dai Z
    J Immunol; 2010 Jul; 185(2):803-7. PubMed ID: 20548035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1.
    Song MY; Park SH; Nam HJ; Choi DH; Sung YC
    J Immunother; 2011 Apr; 34(3):297-306. PubMed ID: 21389868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.